Navigation Links
Researchers discover receptor cells that can cause epilepsy,,

Scientists have made a new discovery regarding the cells that are responsible for causing epileptic seizures // .

Researchers from Wake Forest University School of Medicine have identified glutamate receptor cells in the thalamus area of the brain can slow the release of glutamate when there is brain action that’s associated with seizures. Researchers have found that treatment of epilepsy that will affect the protective glutamate receptors in increasing their potential to check the neural pathway that’s responsible for seizures can benefit the epilepsy patients without having any side effect on the normal functions of the brain.

Epilepsy is a neurological disorder in which sets of cells in brain behave in an abnormal fashion, sending mixed signals to the person suffering from the disease. The symptoms of the condition may be having inappropriate sensations and emotions, behaving inappropriately, or muscle spasms and loss of consciousness.

Epileptic seizures are often related to abnormal neural changes happening in the cerebral cortex that sends wrong neural information to thalamus leading to the symptoms of the seizures. The new study reveals the target that can be treated to control the expression of the epileptic seizures, especially in children.

Reference: Journal of Neurophysiology, July 2005
'"/>




Page: 1

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
8. Researchers reversed the process of memory loss
9. Researchers Identify Key Gene That May Help Brain Treatment
10. Researchers Discover Protein That Causes Malaria
11. Commercialization of Biotech Discoveries, An Encouragement For Researchers
Post Your Comments:
(Date:5/16/2008)...this country needs is more unemployed politicians ...ire-FirstCall/ -- Although nearly all,voters place...ssues" list,a looming federal budgetary crunch me...of the current presidential candidates is likely t... Majority Leader Bill Frist., Jousting with Princ...
(Date:5/16/2008)...RISBURG, Pa., May 16 /PRNewswire-USNewswire/ -- Em...opportunity to highlight the dedication,of Pennsyl...ns to become,trained EMS volunteers, according to ...is year,s theme, "EMS: Your Life is Our Mission," ... when it occurs, EMS is there to provide,immediate...
(Date:5/16/2008)...HINGTON, May 16 /PRNewswire-USNewswire/ -- As trop...f the Irrawaddy delta, survivors of,Cyclone Nargis...ems. Many,survivors still need assistance, as expo...ting an increasingly dire situation., "The people...p to,recover from this disaster and get back on th...
(Date:5/16/2008)...ppeals for Funds Focus on Millions of Children Sti...e U.S. Fund for UNICEF and The,Advertising Council...romote,a series of national public service announc...ing Ben Stiller, Nicole Ritchie, Joel Madden, Davi... to help survivors of the,Myanmar cyclone. The Ad ...
Breaking Medicine News(10 mins):Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:PA Secretary of Health Announces 'Emergency Medical Services Week,' May 18 - 24 2Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3
... the growing problem of obesity in Australians by ...he study, published in the latest edition of The M...elp they wanted from their general practitioner (G... Levels of overweight and obesity in Australia ha...
...gricultural Research (ICAR) has announced the arri...loped by the High Security Animal// Disease Labora...ce in the whole of India that conducts tests for t...ector General Mangala Rai said, "Viral diseases, s...
...leagues, investigators from the Howard Hughes Medi... could help in identifying previously// unknown ge... The researchers by using a new technique, where i... which are present inside acute myeloid leukemia (...
...lowing a cardiac arrest at the work place, the emp... legal heirs// under the Workmen Compensation Act,...loyers' liability for compensation under Section 3...jit Pasayat and Justice L S Panta said "it has to ...
Other Medicine News:Health News:New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer 2Health News:New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer 3
(Date:5/15/2008)...a newly cleared device to identify the, lipid cor...sociated with complications of c...wswire/ -- InfraReDx, Inc. today,announced that ph... have,successfully used its LipiScan(TM) Coronary ...atheterization. This is the first patient in the,w...
(Date:5/15/2008)...RNewswire/ -- Tigris Pharmaceuticals,Inc. announc...nd,Development Agreement (CRADA) with the National... and preclinical development of AFP-464, an,aminof...s converted to,metabolites which bind covalently t... This is part of a four-year CRADA encompassing m...
(Date:5/15/2008)... CEA Trial data reports in third quarter ... /- VIA Pharmaceuticals,In...ed on the development of,compounds for the treatme...,it has completed patient enrollment in its acute ...e of three Phase 2 trials investigating VIA-2291,...
(Date:5/14/2008)...Newswire-FirstCall/ -- Progen,Pharmaceuticals Limi...he,Company has resumed patient enrolment in the ph...ed polyamine analogue, PG-11047 (formerly CGC-1104... commenced development of PG-11047 - the lead clin... following its acquisition of,Cellgate, Inc earlie...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 358 1Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 358 2A step toward tissue engineered heart structures for children 355 1A step toward tissue engineered heart structures for children 355 2Microbiotic technology developed for microinjection of zebrafish embryos 1069 1Mathematics might save you a trip to the ER 1066 1Mathematics might save you a trip to the ER 1066 2
...-May 21, 2007 - Medical,professionals seeking to t...cquired gram-negative pneumonia may have a new wea...ct candidate being,developed by Nektar Therapeutic...rial evaluating the use of,NKTR-061 (Inhaled Amika...h hospital-acquired gram-negative pneumonia were,p...
...ed by FDA for long-term,maintenance treatment of C...bulized formoterol fumarate provides improved lung...anced patient quality of,life, and positive safety... presented at the,International Conference of the ...erforomist™ (formoterol fumarate),Inhalation...
Other Medicine Technology:Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
...lumn of a 384 Well Plate at Once , To increase ef...need a pipettor that can adapt to the narrow well ...annel Impact pipettor., Available with Impact or ...tion was specifically designed to allow you to tra...
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th
...e world leader in peel-away introducers. Our peel-...pacemaker and defibrillator lead implantation, cen...r temporary pacemaker insertions. The advanced des...udes the Di-Lock™ locking dilator and offers...
...ary Self-Expanding Stent System combines low-profi...y in one system. This .018" guide wire compatible ...ter compatibility in all diameters (5.0 - 10.0 mm)....018 system is offered in five stent lengths (28, ...
Medicine Products: